European Journal of Cancer
Издатель: Elsevier · ISSN 0959-8049 · 65 статей
- Letter to the editor Re: Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype
- The APA Score Stratifies Prognosis in Patients with hepatocellular carcinoma Treated with Atezolizumab-Bevacizumab
- Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact
- Letter Re: Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial
- Real-world anti-EGFR rechallenge in circulating tumor DNA-profiled metastatic colorectal cancer: the REalCHALLENGE study
- Beyond Cytotoxic Chemotherapy: Aspirin and Structured Exercise to Reduce Colorectal Cancer Recurrence
- Clinicogenomic Landscape of Small Cell Carcinoma and Identification of Potentially Actionable Genomic Alterations by Comprehensive Genomic Profiling
- Effectiveness of remote symptom monitoring with clinical feedback in patients with breast cancer under active treatment: Systematic review and meta-analysis
- Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dutch National and US institutional cohort
- First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort
- Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study
- Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer
- Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer
- Frozen section analysis assisted MRI targeted prostate biopsy - results of the randomized clinical FAST trial
- Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial
- A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study
- Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey
- Pain in epithelioid hemangioendothelioma: Development of disease-specific pain assessment criteria (PAC-E)
- Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study
- Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study
- Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study
- Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody–drug conjugates: A literature review
- Single-item measures of perceived side effect burden for people with cancer: A systematic scoping review
- Systemic inflammation and patient-reported quality of life as combined prognosticators in patients with solid tumors
- Recent trends in childhood, teenage and young adult cancer incidence in England (2001–2020)
- The UK’s radiotherapy workforce shortage: Reforming regulation to address the gap
- Liquid biopsy tumour fraction, total tumour volume, and automated whole-body CT body composition for survival stratification in metastatic cancer: A temporally validated pan-cancer cohort study
- Refining neoplasm risk in DICER1-related tumor predisposition
- Letter Re: “A stromal–immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study”
- Response to the letter RE: Assessing the magnitude of surveillance bias in prostate cancer, melanoma and lung cancer